This dual effect suggests a complex dynamic where CDK4/6 inhibitors may enhance the immune recognition of tumor cells but limit the expansion of T cell populations, potentially influencing the overall effectiveness of immune responses during treatment [35]. This evidence concerns the gene CDK4 and neoplasm.